Bicalutamide (Casodex®)

Common name: Bicalutamide
Brand name: Casodex®
 

What is Bicalutamide?

Bicalutamide is a non-steroidal anti-androgen used to treat advanced (metastatic) prostate cancer. It works by reducing the amount of testosterone in the body.  Bicalutamide may be given in combination with other hormonal therapies such as luteinizing hormone releasing hormone (LHRH) analogues or in the surgical removal of the testicles (castration).
 

How is Bicalutamide administered?

Bicalutamide is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received bicalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Constipation
  • Decreased libido
  • High blood pressure
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Loss of appetite
  • Nausea
  • Muscle weakness
  • Swelling of breasts
 

Is Bicalutamide covered in my province or territory?*

Bicalutamide is covered by all provincial/territorial drug programs.

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=22652
 
Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive